PL2773955T3 - Przesiewanie leków i testy siły - Google Patents

Przesiewanie leków i testy siły

Info

Publication number
PL2773955T3
PL2773955T3 PL12787307T PL12787307T PL2773955T3 PL 2773955 T3 PL2773955 T3 PL 2773955T3 PL 12787307 T PL12787307 T PL 12787307T PL 12787307 T PL12787307 T PL 12787307T PL 2773955 T3 PL2773955 T3 PL 2773955T3
Authority
PL
Poland
Prior art keywords
drug screening
potency assays
potency
assays
screening
Prior art date
Application number
PL12787307T
Other languages
English (en)
Inventor
Andrew T. Bruce
Russel W. KELLEY
Timothy A. Bertram
Sumana Choudhury
Joydeep Basu
Original Assignee
Inregen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inregen filed Critical Inregen
Publication of PL2773955T3 publication Critical patent/PL2773955T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12787307T 2011-11-04 2012-11-05 Przesiewanie leków i testy siły PL2773955T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556133P 2011-11-04 2011-11-04
US201161560679P 2011-11-16 2011-11-16
US201261689245P 2012-06-01 2012-06-01
EP12787307.3A EP2773955B1 (en) 2011-11-04 2012-11-05 Drug screening and potency assays
PCT/US2012/063556 WO2013067498A1 (en) 2011-11-04 2012-11-05 Drug screening and potency assays

Publications (1)

Publication Number Publication Date
PL2773955T3 true PL2773955T3 (pl) 2018-12-31

Family

ID=47178990

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12787307T PL2773955T3 (pl) 2011-11-04 2012-11-05 Przesiewanie leków i testy siły

Country Status (8)

Country Link
US (2) US20140308695A1 (pl)
EP (2) EP3425391A1 (pl)
JP (3) JP2014532431A (pl)
DK (1) DK2773955T3 (pl)
ES (1) ES2689265T3 (pl)
PL (1) PL2773955T3 (pl)
PT (1) PT2773955T (pl)
WO (1) WO2013067498A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
PL2773955T3 (pl) * 2011-11-04 2018-12-31 Inregen Przesiewanie leków i testy siły
EP3567099B1 (en) 2012-10-24 2021-04-21 ProKidney Renal cell populations and uses thereof
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CN107002033B (zh) 2014-10-06 2021-08-10 奥加诺沃公司 工程化肾组织、其阵列及其制备方法
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
US10663456B2 (en) 2015-07-24 2020-05-26 National Institute Of Advanced Industrial Science And Technology Method for measuring in vivo inhibition of intracellular RNase
AU2016318114B2 (en) * 2015-09-03 2023-04-20 The Brigham And Women's Hospital, Inc. Three-dimensional differentiation of epiblast spheroids to kidney organoids models stage-specific epithelial physiology, morphogenesis, and disease
WO2017091147A1 (en) * 2015-11-20 2017-06-01 Agency For Science, Technology And Research High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures
KR101816595B1 (ko) * 2016-03-04 2018-01-10 부산대학교 산학협력단 리보솜 작용 저해제를 유효성분으로 함유하는 암줄기세포로의 탈분화 유도용 조성물
JP7112957B2 (ja) * 2016-03-09 2022-08-04 ベイジン パーカンズ オンコロジー カンパニー リミテッド 腫瘍細胞懸濁培養及び関連方法
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US11268950B2 (en) * 2016-09-28 2022-03-08 Organovo, Inc. Use of engineered renal tissues in assays
AU2017373767B2 (en) 2016-12-05 2021-09-16 Children's Hospital Medical Center Colonic organoids and methods of making and using same
JP7141688B2 (ja) * 2018-05-15 2022-09-26 学校法人北里研究所 近位尿細管上皮細胞株及びその使用
MX2021001722A (es) * 2018-08-31 2021-07-15 Timothy A Bertram Composiciones que comprenden vesiculas derivadas de celulas y usos de las mismas.
EP3847274A4 (en) * 2018-09-05 2022-06-08 Readcoor, LLC METHODS AND SYSTEMS FOR THERAPEUTIC AGENT ANALYSIS
EP4167347A1 (en) 2020-06-15 2023-04-19 Mitsui Chemicals, Inc. Metal-resin complex, cooling device, method for manufacturing metal-resin complex, and safety valve structure
CN113960302B (zh) * 2021-09-29 2024-04-23 中国人民解放军军事科学院军事医学研究院 一种基于高内涵技术的肾毒性检测方法及其应用
CN116609525B (zh) * 2023-05-26 2023-10-27 杭州圣域生物医药科技有限公司 基于细胞内aldh3b1蛋白水平以筛选染色质重塑复合体抑制剂的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
WO2000073791A1 (en) * 1999-05-27 2000-12-07 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
WO2004059276A2 (en) * 2002-12-31 2004-07-15 Pfizer Products Inc. Rna bioassay
WO2004065616A2 (en) * 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
WO2007095193A2 (en) 2006-02-10 2007-08-23 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
JP5974233B2 (ja) 2008-11-12 2016-08-24 リージェンメド（ケイマン）エルティーディー． 単離した腎細胞およびその使用
WO2010150613A1 (ja) * 2009-06-26 2010-12-29 国立大学法人宮崎大学 急性腎不全の診断方法
WO2011060298A1 (en) * 2009-11-12 2011-05-19 Tengion, Inc. Rational design of regenerative medicine products
US20120179381A1 (en) * 2010-06-17 2012-07-12 Mckim James M Toxicity screening methods
PL2773955T3 (pl) * 2011-11-04 2018-12-31 Inregen Przesiewanie leków i testy siły

Also Published As

Publication number Publication date
US20170205398A1 (en) 2017-07-20
ES2689265T3 (es) 2018-11-12
JP2020103294A (ja) 2020-07-09
JP2017148039A (ja) 2017-08-31
EP3425391A1 (en) 2019-01-09
PT2773955T (pt) 2018-10-26
EP2773955A1 (en) 2014-09-10
US20140308695A1 (en) 2014-10-16
WO2013067498A1 (en) 2013-05-10
DK2773955T3 (en) 2018-09-24
JP2014532431A (ja) 2014-12-08
EP2773955B1 (en) 2018-07-18
JP6661560B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
PT2773955T (pt) Triagem de fármaco e ensaios de potência
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2777074A4 (en) DRUG SCREENING PROCESSES AND APPLICATIONS THEREOF
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL229315A0 (en) chaperone protein interaction assays and their uses
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
HK1200486A1 (en) Screening methods and uses thereof
GB201012272D0 (en) Assays for screening drug safety
GB201107697D0 (en) Drug screening